Inadequate treatment of congestive heart failure in dialysis patients.

Abstract

Congestive heart failure (CHF) is highly prevalent in patients on renal replacement therapy and is a leading cause of death in such patients. Several studies suggest that therapeutic agents for the treatment of CHF, particularly angiotensin converting enzyme inhibitors and beta-blockers, are underused in end-stage renal disease patients with CHF. Although limited data are available, growing evidence suggests that therapeutic agents for CHF improve survival and are safe to use, assuming close monitoring of adverse events. The reluctance of physicians in prescribing these therapeutic agents and the reasons underlying the inconsistent use of these agents in the dialysis population need to be addressed.

• Authors: Josée Bouchard, François Madore
• Journal: Seminars in dialysis (Semin Dial) 2007 Sep-Oct Vol. 20 Issue 5 Pg. 383-6 ISSN: 0894-0959 [Print] United States
• PMID: 17897240 (Publication Type: Editorial)

Chemical References

• Adrenergic beta-Antagonists
• Angiotensin-Converting Enzyme Inhibitors

Topics

• Adrenergic beta-Antagonists (therapeutic use)
• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Dialysis
• Drug Prescriptions (standards)
• Heart Failure (complications, drug therapy)
• Humans
• Kidney Failure, Chronic (complications, therapy)
• Treatment Failure